Hematology

Piatek discussed findings from a healthcare resource utilization study and a sentiment analysis study presented at ASH 2024.

Pipe discussed a symposium at ASH 2024 about practical implementation of gene therapy in the field.

Schultz discussed the SCtalk trial and its findings at ASH 2024.

Zaheer discussed how this research may be used as a model to help study other therapy transitions as well.

Bendapudi gave an overview of 2 studies presented at ASH 2024 from his Harvard lab.

Rani discussed an in-depth study examining quality of sleep and quality of life in children and adolescents with SCD.

A study shows that a lower non-HDL/HDL cholesterol ratio is linked to greater anemia prevalence. A threshold of 4.28 shows a 15% anemia risk drop per unit increase below this value.

Concizumab marks the first subcutaneous injection treatment for hemophilia A or B with inhibitors, demonstrating an 86% reduction in bleeds in pivotal trial data.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

A hematologist discusses the role of internal and family medicine practitioners in improving the diagnosis and management of iron deficiency.

Steven Fein, MD, discusses news and updates in sickle cell disease following ASH 2024.

Real-world clinical data from the Adelphi PNH II Disease Specific Programme were reported at ASH 2024.

Danicopan add-on therapy demonstrated more favorable safety in the ALPHA trial than pegcetacoplan did in the PEGASUS trial in a new analysis.

At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.

Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.

Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.

Data from the PINES trial at ASH 2024 suggest eltrombopag could outperform current standard of care for platelet response in newly diagnosed pediatric ITP.

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibody’s anti-inflammatory action.

Topline results from APPULSE-PNH show the positive efficacy and safety of twice-daily oral iptacopan in adults with PNH switched from anti-C5 therapies.

Dexamethasone treatment was linked to worse clinical outcomes in patients with sickle cell disease hospitalized for COVID-19.

Anemia in heart failure with preserved ejection fraction was linked to right ventricular dysfunction in an analysis of more than 1000 patients in China.